| Study | Reason for exclusion |
|---|---|
| AGATE‐I 2015 | All arms were treated with DAAs |
| ALLY 2015 | All participants were treated with DAAs |
| ANNAPURNA 2013 | All participants were treated with DAAs |
| APRICOT 2004 | Participants were not treated with DAAs |
| ATOMIC 2013 | All participants were treated with DAAs |
| ATTAIN 2015 | All participants were treated with DAAs |
| AVIATOR 2015 | Not a randomised clinical trial. All participants were treated with DAAs |
| Basu 2014b | The trial compared same treatment regimens (simeprevir 150 mg and sofosbuvir 400 mg) with concomitant different dosages of RBV (modified doses vs 1000 mg) and different treatment duration (24 weeks vs 16 weeks) |
| Bathgate 2011 | Short review written as 'Clinical opinion' for RESPOND‐2 and SPRINT‐2 trials |
| Bognar 2011 | A Markov model simulation |
| Bourgeois 2015 | Wrong control (different doses of simeprevir) |
| C‐SURFER 2015 | All participants were treated with DAAs |
| C‐WORTHY 2015 | All participants were treated with DAAs |
| Chandra 2006b | Participants were healthy |
| CONCISE 2013 | All participants were treated with DAAs |
| COSMOS 2014 | All participants were treated with DAAs |
| Di Bisceglie 2014 | The trial compared the same treatment in equal or different dosages (telaprevir and VX‐222) combined with or without peg‐IFN and RBV |
| Dore 2014 | Pooled analysis from two different trials |
| Dusheiko 2015 | Was an analyses of multiple trials. It was not clear which trials the study looked at. |
| Ferenci 2014 | Wrong intervention (trial does not actually compare DAA with placebo/other medical intervention) |
| Ferrante 2011a | A Markov model projection |
| Ferrante 2011b | A Markov model projection |
| Ferrante 2013 | A Markov model projection |
| Foster 2010 | Pooled analysis of data from different trials |
| FOURward 2014 | Parallel‐group design, no control arm |
| FUSION 2013 | No control arm |
| Gardner 2014b | Participants were healthy |
| HCVerso 1 2014 | No control group |
| HCVerso 2 2014 | No control group |
| ION‐3 2014 | Parallel‐group design, no control arm |
| Jacobson 2013 | Pooled analysis from two different trials |
| Kawada 2015 | Wrong control |
| Liu 2015b | RBV was assessed as active treatment |
| Lok 2010 | Wrong control (different doses of DAA) |
| Lok 2011 | Wrong control (different doses of DAA) |
| Lok 2012a | Wrong control (different doses of DAA) |
| Lok 2012b | Wrong control (different doses of DAA) |
| Lok 2014 | Wrong control (different doses of DAA) |
| MALACHITE‐I 2016 | Wrong control group (control group received another DAA) |
| MALACHITE‐II 2016 | Wrong control group (control group received another DAA) |
| Manns 2014b | Combined analysis of 3 trials |
| Manns 2015 | Compared the same treatment (ledipasvir/sofosbuvir + RBV) of different duration (12 weeks vs 24 weeks) |
| Mendez 2014 | Not a randomised clinical trial (compared other trials) |
| Mizokami 2015 | Wrong intervention/control (compared RBV vs no RBV) |
| Molina 2015 | Not randomised |
| Muir 2011 | Not randomised |
| Muir 2015 | Not randomised |
| NEUTRINO 2013 | Single‐group, open label study |
| Nishiguchi 2014b | No control group |
| Nomura 2014 | Not randomised |
| NUCLEAR 2013 | Parallel‐group design, no control arm |
| OPTIMIST‐1 2015 | Parallel‐group design, no control group |
| OPTIMIZE 2013 | Wrong control (different time points of telaprevir) |
| Poordad 2014 | The trial compared different treatment durations (12 weeks vs 24 weeks) of the same treatment regimen (ABT‐450/r‐ombitasvir, dasabuvir, and RBV) |
| Proulx 2008 | Healthy volunteers |
| Reddy 2011 | Combined analysis of three trials |
| Serfaty 2012 | Wrong control (all groups received DAA) |
| Sulkowski 2011 | Retrospective study |
| Sulkowski 2012a | Wrong intervention/control (The trial compared ribavirin versus no ribavirin). Same as Sulkowski 2014 (NCT01359644) |
| Sulkowski 2012b | Wrong control group (no groups could be used as control) |
| Sulkowski 2013d | Trial comparing different dosages of the same DAA |
| Sulkowski 2014 | Wrong intervention/control (compared RBV versus no RBV) |
| Zeuzem 2012 | Study evaluating 5 arms of participants treated with same drug regimen comparing different dosages, treatment durations, and/or RBV co‐intervention |
| Zeuzem 2013 | Evaluated different dosages of the same treatment regimen |
| Zeuzem 2014b | The trial was initially designed as a multicenter, phase 3, randomised, placebo‐controlled, double‐blind trial of sofosbuvir + RBV vs placebo + RBV. Based on new published information, the protocol was amended and the study was redefined as a descriptive study in which the groups were unblinded, the placebo group was terminated, and the study assessed sofosbuvir + RBV for 12 weeks vs sofosbuvir + RBV for 24 weeks |
DAA: direct‐acting antivirals; HCV: hepatitis C virus; peg‐IFN: pegylated interferon; RBV: ribavirin; vs: versus